drug_type
RELEVANT_DRUG
intervention_type
Personalized adoptive cellular immunotherapy (autologous gene-modified T-cell biologic)
drug_description
Autologous CD8+ T cells genetically engineered (gene-edited, TCR-transduced) with a personalized, multi-target, tumor-specific TCR set; administered as sequential IV infusions to redirect T-cell receptor specificity to patient-specific HLA class I–presented tumor antigens and drive cytotoxic effector activity (cytokine release, perforin/granzyme-mediated killing).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD8+ T cells are gene-edited and TCR-transduced to express a personalized set of tumor-specific T-cell receptors that recognize patient-specific peptide–HLA class I complexes on tumor cells, activating TCR signaling and cytotoxic effector functions (cytokine release, perforin/granzyme-mediated killing) to eliminate cancer cells.
drug_name
TCRx T cells
nct_id_drug_ref
NCT05447234